B-cell Biology and Related Therapies in Systemic Lupus Erythematosus

Rheumatic Disease Clinics of North America

Volumn 36, Issue 1, 2010, Pages 109-130

  Ahmed, Sadia ^a   Anolik, Jennifer H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anti CD20; Atacicept; B lymphocytes; Belimumab; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ANTIBODY; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR RECEPTOR 3 ANTIBODY; B CELL ACTIVATING FACTOR RECEPTOR 3 FC; BELIMUMAB; CD40 LIGAND ANTIBODY; CYCLOPHOSPHAMIDE; EPRATUZUMAB; IMMUNOGLOBULIN; INTERFERON; MYCOPHENOLIC ACID; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; TOLL LIKE RECEPTOR; TRU 015; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CLINICAL TRIAL; CYTOLOGY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECOMBINANT FUSION PROTEINS;

EID: 77349093568     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.12.002     Document Type: Review

References (123)

1. Bongu A., Chang E., and Ramsey-Goldman R. Can morbidity and mortality of SLE be improved?. Best Pract Res Clin Rheumatol 16 (2002) 313-332
2. Gordon C., Bertsias G.K., Ioannidis J.P., et al. EULAR recommendations for points to consider in conducting clinical trials in systemic lupus erythematosus (SLE) [review]. Ann Rheum Dis 68 4 (2009) 470-476
3. Dall'Era M., and Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol 18 5 (2006) 476-480
4. Bertsias G., Gordon C., and Boumpas D.T. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future-the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 17 5 (2008) 437-442
5. Chan O.T., Hannum L.G., Haberman A.M., et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189 10 (1999) 1639-1648
6. Arbuckle M., McClain M., Rubertone M., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 16 (2003) 1526-1533
7. Kumar K.R., Li L., Yan M., et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 312 5780 (2006) 1665-1669
8. Bolland S., and Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13 2 (2000) 277-285
9. Fukuyama H., Nimmerjahn F., and Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6 1 (2005) 99-106
10. McGaha T.L., Sorrentino B., and Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307 5709 (2005) 590-593
11. Floto R.A., Clatworthy M.R., Heilbronn K.R., et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med 11 10 (2005) 1056-1058
12. Mackay M., Stanevsky A., Wang T., et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 203 9 (2006) 2157-2164
13. Liossis S.N., Kovacs B., Dennis G., et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98 11 (1996) 2549-2557
14. Olferiev M., and Crow M. Activation of interferon and ubiquitin pathways in lupus memory B cells. Arthritis Rheum 60 Suppl 10 (2009) S744
15. Mackay F., Woodcock S., Lawton P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
16. Gross J., Johnston J., and Mudri S. TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature 404 (2000) 995-999
17. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 12 (2003) 3475-3486
18. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF [comment]. Immunity 20 4 (2004) 441-453
19. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 6 (2004) 785-798
20. Miller J., Stadanlick J.E., and Cancro M.P. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 176 (2006) 6405-6410
21. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors [comment]. Nature 416 6881 (2002) 603-607
22. Viglianti G.A., Lau C.M., Hanley T.M., et al. Activation of autoreactive B cells by CpG dsDNA. Immunity 19 6 (2003) 837-847
23. Boule M.W., Broughton C., Mackay F., et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199 12 (2004) 1631-1640
24. Means T.K., Latz E., Hayashi F., et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115 2 (2005) 407-417
25. Yurasov S., Wardemann H., Hammersen J., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201 5 (2005) 703-711
26. Cappione III A., Anolik J.H., Pugh-Bernard A., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115 11 (2005) 3205-3216
27. Pugh-Bernard A.E., Silverman G.J., Cappione A.J., et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 108 7 (2001) 1061-1070
28. Tsuiji M., Yurasov S., Velinzon K., et al. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 203 2 (2006) 393-400
29. Wardemann H., Yurasov S., Schaefer A., et al. Predominant autoantibody production by early human B cell precursors. Science 301 (2003) 1374-1377
30. Grammer A., and Lipsky P.E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5 (2003) S22-S27
31. Odendahl M., Jacobi A., Hansen A., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165 (2000) 5970-5979
32. Anolik J., Barnard J., Cappione A., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
33. Wei C., Anolik J., Cappione A., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178 10 (2007) 6624-6633
34. Jacobi A.M., Reiter K., Mackay M., et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 58 6 (2008) 1762-1773
35. Jacobi A.M., Odendahl M., Reiter K., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48 5 (2003) 1332-1342
36. Jacobi A.M., Mei H., Hoyer B.F., et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with SLE. Ann Rheum Dis 69 1 (2010) 305-308
37. Wei C., Palanichamy A., Jenks S., et al. B Cell signatures as biomarkers in SLE. Arthritis Rheum 60 Suppl 10 (2009) 1764
38. Arce E., Jackson D.G., Gill M.A., et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 167 4 (2001) 2361-2369
39. Palanichamy A., Barnard J., Zheng B., et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 182 10 (2009) 5982-5993
40. Sabahi R., Owen T., Barnard J., et al. Immunologic effects of BAFF antagonism in the treatment of human SLE. Arthritis Rheum 56 (2007) S566
41. Shlomchik M.J., Madaio M.P., Ni D., et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 180 4 (1994) 1295-1306
42. Bekar K, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus [abstract]. Arthritis Rheum 2009;60(Suppl 10):677.
43. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 8 (2004) 2580-2589
44. Lorenz R.G., Chaplin D.D., McDonald K.G., et al. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol 170 11 (2003) 5475-5482
45. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23 (2005) 787-819
46. Chang A, Henderson S, Liu N, et al. In situ B cell mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. 2010.
47. Harris D., Haynes L., Sayles P., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1 (2000) 475-481
48. Ebert L.M., Horn M.P., Lang A.B., et al. B cells alter the phenotype and function of follicular-homing CXCR5+ T cells. Eur J Immunol 34 12 (2004) 3562-3571
49. Odegard J.M., Marks B.R., DiPlacido L.D., et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 205 12 (2008) 2873-2886
50. Vinuesa C.G., Cook M.C., Angelucci C., et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435 7041 (2005) 452-458
51. Lund F.E. Cytokine-producing B lymphocytes - key regulators of immunity. Curr Opin Immunol 20 3 (2008) 332-338
52. Fillatreau S., Gray D., and Anderton S.M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8 5 (2008) 391-397
53. Lampropoulou V., Hoehlig K., Roch T., et al. TLR-Activated B cells suppress T cell-mediated autoimmunity. J Immunol 180 7 (2008) 4763-4773
54. Fillatreau S., Sweenie C.H., McGeachy M.J., et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3 10 (2002) 944-950
55. Mauri C., Gray D., Mushtaq N., et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197 4 (2003) 489-501
56. Chen X., and Jensen P.E. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 179 4 (2007) 2046-2050
57. Mann M.K., Maresz K., Shriver L.P., et al. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 178 6 (2007) 3447-3456
58. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24 (2006) 467-496
59. Bave U., Alm G.V., and Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 165 6 (2000) 3519-3526
60. Bave U., Magnusson M., Eloranta M., et al. Fc gamma RIIa is expressed on natural IFN-alpha producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 171 (2003) 3296-3302
61. Ronnblom L., and Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus [comment]. J Exp Med 194 12 (2001) F59-F63
62. Christensen S.R., Shupe J., Nickerson K., et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus [comment]. Immunity 25 3 (2006) 417-428
63. Herlands R.A., Christensen S.R., Sweet R.A., et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 29 2 (2008) 249-260
64. Ehlers M., Fukuyama H., McGaha T.L., et al. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 203 3 (2006) 553-561
65. Pisitkun P., Deane J.A., Difilippantonio M.J., et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 5780 (2006) 1669-1672
66. Jego G., Palucka A.K., Blanck J.P., et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 2 (2003) 225-234
67. Bekeredjian-Ding I.B., Wagner M., Hornung V., et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 174 7 (2005) 4043-4050
68. Uccellini M.B., Busconi L., Green N.M., et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol 181 9 (2008) 5875-5884
69. Barnard J., Palanichamy A., Bauer J., et al. Interferon activation in human SLE bone marrow inhibits B cell lymphopoeisis. Arthritis Rheum 10 11 (2008)
70. Hoyer B., Moser K., Hauser A., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199 (2004) 1577
71. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 9 (1994) 450-454
72. Maloney D.G., Smith B., and Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 29 1 Suppl 2 (2002) 2-9
73. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
74. Mamani-Matsuda M., Cosma A., Weller S., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111 9 (2008) 4653-4659
75. Vos K., Thurlings R.M., Wijbrandts C.A., et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56 3 (2007) 772-778
76. Levesque M.C. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 157 2 (2009) 198-208
77. Albert D., Dunham J., Khan S., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67 12 (2008) 1724-1731
78. Lindholm C., Borjesson-Asp K., Zendjanchi K., et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35 5 (2008) 826-833
79. Jonsdottir T., Gunnarsson I., Risselada A., et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67 3 (2008) 330-334
80. Amoura Z., Mazodier K., Michel M., et al. Efficacy of rituximab in systemic lupus erythematosus: a series of 22 cases. Arthritis Rheum 56 9 (2007) S458
81. Lu T.Y., Ng K.P., Cambridge G., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61 4 (2009) 482-487
82. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17 5 (2005) 550-557
83. Ramos-Casals M., Soto M.J., Cuadrado M.J., et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 9 (2009) 767-776
84. Karpouzas G., Gogia M., Moran R., et al. Rituximab therapy induces durable remissions in Hispanic and African American patients with refractory systemic lupus erythematosus (SLE). Arthritis Rheum 60 Suppl 10 (2009) 274
85. Terrier B., Hachulla E., and Pallot-Prades B. Tolerance and efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE): data of 104 patients from the AIR (Auto-immunity and Rituximab) Registry. Arthritis Rheum 60 Suppl 10 (2009) 272
86. Anolik J.H., Barnard J., Owen T., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56 9 (2007) 3044-3056
87. Merrill J, Neuwelt C, Wallace D, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. American College of Rheumatology Annual Meeting. October 29, 2008. Available at: www.abstractsonline.com.
88. Gunnarsson I., Sundelin B., Jonsdottir T., et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56 4 (2007) 1263-1272
89. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 2 (2005) 501-513
90. Melander C., Sallee M., Trolliet P., et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4 3 (2009) 579-587
91. Pepper R., Griffith M., Kirwan C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24 12 (2009) 3717-3723
92. Li E.K., Tam L.S., Zhu T.Y., et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology (Oxford) 48 8 (2009) 892-898
93. Furie R., Looney J., Rovin B., et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 60 Suppl 10 (2009) 1149
94. Isenberg D., Gordon C., Merrill J., et al. New therapies in systemic lupus erythematosus - trials, troubles and tribulations. Working towards a solution. Lupus 17 11 (2008) 967-970
95. Looney J., Anolik J., and Sanz I. A perspective on B-cell targeting therapy for SLE. Mod Rheumatol (2009) [Epub ahead of print]
96. Coca A, Anolik J. Two negative randomized controlled trials in lupus: now what? F1000 Medicine Reports 2009;1:28.
97. Cambridge G., Stohl W., Leandro M., et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 3 (2006) 723-732
98. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 1 (2005) 262-268
99. Rouziere A.-S., Kneitz C., Palanichamy A., et al. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 7 4 (2005) R714-R724
100. Sfikakis P., Boletis J., Lionaki S., et al. Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 50 (2004) S227
101. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., et al. Clinical and immunologic effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8 (2006) R83
102. Hu C., Rodriguez-Pinto D., Du W., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117 12 (2007) 3857-3867
103. Looney R.J., Srinivasan R., and Calabrese L.H. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58 1 (2008) 5-14
104. van der Kolk L., Baars J., Prins M., et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100 (2002) 2257-2259
105. Bearden C.M., Agarwal A., Book B.K., et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 5 1 (2005) 50-57
106. Cambridge G., Leandro M.J., Edwards J.C., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 8 (2003) 2146-2154
107. Willems M., Haddad E., Niaudet P., et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148 5 (2006) 623-627
108. Zecca M., Nobili B., Ramenghi U., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 10 (2003) 3857-3861
109. Salliot C., Dougados M., and Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68 1 (2009) 25-32
110. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 12 (2007) 3896-3908
111. Genovese M.C., Breedveld F.C., Emery P., et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 68 (2009) 1894-1897
112. Carson K.R., Focosi D., Major E.O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10 8 (2009) 816-824
113. Calabrese L.H., and Molloy E.S. Therapy: rituximab and PML risk-informed decisions needed!. Nat Rev Rheumatol 5 10 (2009) 528-529
114. Yazawa N., Hamaguchi Y., Poe J.C., et al. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A 102 42 (2005) 15178-15183
115. Wang X., Huang W., Schiffer L.E., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48 2 (2003) 495-506
116. Kalunian K.C., Davis Jr. J.C., Merrill J.T., et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 12 (2002) 3251-3258
117. Boumpas D.T., Furie R., Manzi S., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 3 (2003) 719-727
118. Huang W., Sinha J., Newman J., et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46 (2002) 1554-1562
119. Daikh D.I., and Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 166 5 (2001) 2913-2916
120. Chang S.K., Mihalcik S.A., and Jelinek D.F. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 180 11 (2008) 7394-7403
121. Dall'Era M., Chakravarty E., Wallace D., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56 12 (2007) 4142-4150
122. Munafo A., Priestley A., Nestorov I., et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63 7 (2007) 647-656
123. Neubert K., Meister S., Moser K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14 7 (2008) 748-755